Cat NO.:	EL0153Hu
Product:	Sunlong Medical™ Human CXCL5/ENA-78 ELISA Kit
Storage	4℃ (unopened) for two years
Shipping Condition	4℃
Sample Type:	Serum | plasma | cell culture supernatant and other biological samples
Spike Recovery Range:	82% - 125%
Mean Spike Recovery:	1.01
CV of Intra plate:	4.9 % - 6.4 %
CV of Inter plate:	2.8 % - 3.9 %
NCBI_Gene:	6374
UniProtKB:	P42830

 

PLATFORM	ELISA
PLATE	Detachable 96-well plate
SIZE	96T/48T
STORAGE	If the reagent kit is unopened, it should be stored at 4℃. However, if it has been opened, the standard solution should be stored at -20℃, while the other components should be stored at 4℃.
DELIVERY	4℃ blue ice transportation
COMPONENTS	96-well polystyrene enzyme-linked immunosorbent assay (ELISA) plate coated with anti-CXCL5 monoclonal antibody Human CXCL5 freeze-dried standard CXCL5 detect Antibody Standard Diluent HRP-labeled streptavidin Assay Buffer(10×) Substrate TMB Stop Solution Washing Buffer(20×) Sealing Film
ASSAY PRINCIPLE	This kit utilizes the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection technique.Specific anti-human CXCL5 antibodies are precoated on a high-affinity ELISA plate.Standards and test samples are added to the wells of the ELISA plate. After incubation, the CXCL5 present in the samples binds to the solid-phase antibodies. After washing to remove unbound substances, biotinylated detection antibodies are added and incubated. After washing to remove unbound biotinylated antibodies, streptavidin-HRP labeled with horseradish peroxidase is added. After washing, the TMB chromogenic substrate is added, and color development is carried out while avoiding light. The intensity of the color reaction is directly proportional to the concentration of CXCL5 in the samples. A stop solution is added to terminate the reaction, and the absorbance value is measured at a wavelength of 450 nm (with a reference wavelength range of 570-630 nm).

 An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma

Cancer Discovery 2023-07-24

Constraint-induced movement therapy alleviates motor impairment by inhibiting the accumulation of neutrophil extracellular traps in ischemic cortex

NEUROBIOLOGY OF DISEASE 2023-03-05

Cartpieces

• 
• 1

  1Delete

• 
• 6

  6Delete

• 
• E

  EDelete

• 
• S

  SDelete

• 
• +

  +Delete

• 
• 7

  7Delete

• 
• 2

  2Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 5

  5Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• S

  SDelete

• 
• C

  CDelete

• 
• <

  <Delete

• 
• i

  iDelete

• 
• i

  iDelete

• Delete

• 
• 1

  1Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• Delete

• 
• 2

  2Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• Delete

• 
• -

  -Delete

• 
• -

  -Delete

• 
• 0

  0Delete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• f

  fDelete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• Delete

• 
• <

  <Delete

• Delete

• 
• S

  SDelete

• Delete

• Delete

• 
• 5

  5Delete

• 
• $

  $Delete

• Delete

• 
• 0

  0Delete

• Delete

• Delete

• Delete

• 
• b

  bDelete

• 
• S

  SDelete

• 
• 5

  5Delete

• 
• S

  SDelete

Totalgoods,subtotals:￥Checkout